Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)

Summary

The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promotes the transfer of the latest scientific knowledge into standard care. The DigiNet project is based on the established precision medicine program, the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, whereby every patient receives molecular diagnostics and personalized therapy information after the initial diagnosis. Within the framework of the DigiNet project, specialized academic centers will be digitally connected with practitioners via a shared project database. Furthermore, a committee of experts will monitor the course of treatment and will advise the practitioners in case of critical conditions. Additionally, patient-reported outcomes will be incorporated into the treatment.

Conditions

• Non-small Cell Lung Cancer Stage IV

Interventions

OTHER

DigiNet intervention

Patients with initial diagnosis of NSCLC stage IV in the model region receiving the following interventions: * broad NGS-based molecular diagnostics and, based thereupon, personalized treatment information within the national Network Genomic Medicine (nNGM) lung cancer * regular clinical follow-up visits and data documentation in the shared central digital database by participating physicians * monthly assessment of patient-reported outcomes (PRO) on quality of life, anxiety, and depression * incorporation of PROs into treatment by physicians * treatment monitoring and counseling in the case of critical conditions by expert committee

Sponsors & Collaborators

• Gemeinsamer Bundesausschuss (G-BA)

  collaborator UNKNOWN

• AOK Rheinland/Hamburg

  collaborator INDUSTRY

• AOK Nordwest

  collaborator INDUSTRY

• BARMER

  collaborator OTHER

• University Hospital, Essen

  collaborator OTHER

• Charite University, Berlin, Germany

  collaborator OTHER

• Berlin Institute of Health

  collaborator OTHER

• Helios Klinikum Emil von Behring

  collaborator UNKNOWN

• University Hospital Carl Gustav Carus

  collaborator OTHER

• Deutsche Krebsgesellschaft e.V.

  collaborator OTHER

• Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V.

  collaborator UNKNOWN

• AOK Bundesverband

  collaborator UNKNOWN

• FOM Hochschule für Oekonomie und Management

  collaborator UNKNOWN

• University Medicine Greifswald

  collaborator OTHER

• Technische Universität Dresden

  collaborator OTHER

• University of Cologne

  lead OTHER

Principal Investigators

• Jürgen Wolf, Prof. Dr. · Uniklinik Köln

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-06-01

Primary Completion

2025-03-31

Completion

2025-03-31

Countries

• Germany

Study Locations